Skip to content

Lung Ultrasound in Children With Severe Malaria

Point of Care Lung Ultrasound to Differentiate Causes of Respiratory Distress in Children With Severe Malaria

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04176029
Acronym
LUSiSM
Enrollment
124
Registered
2019-11-25
Start date
2019-12-09
Completion date
2021-10-30
Last updated
2022-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Malaria

Keywords

severe malaria, lung ultrasound, prevalence of pulmonary diagnoses

Brief summary

A prospective cohort study, with 171 children admitted for severe malaria that will be included in the cohort. The study will take place in Kinshasa, Democratic Republic of Congo. The primary objective is to evaluate the prevalence of five pre-specified pulmonary diagnoses that can be facilitated by the use of LUS (normal lung or acidotic breathing, ARDS, concomitant pneumonia, hydrostatic pulmonary oedema, pleural effusion).

Detailed description

A prospective cohort study, with 171 children (between 1 - 14 years) admitted for severe malaria that will be included in the cohort. The study will take place at the Maluku District Hospital, located in Kinshasa, Democratic Republic of Congo. Lung ultrasound will be performed on admission, h24, and unscheduled timepoints (in case of respiratory deterioration during hospital stay). Lung auscultation and peripheral capillary oxygen saturation (SpO2) will be assessed at each time points. All children will be observed from admission to hospital discharge. At 30 days a phone call will be made by the study staff to follow up clinical conditions of the child. The total duration for each subject's participation in the study is approximately 1 month. The study period is approximately 12 months Funder: The Wellcome Trust (ITPA grant) WT-iTP-2019/005

Interventions

DEVICElung ultrasound

Lung ultrasound is performed using an 12-regions technique i.e. six areas on each side of the chest, two ventral, two lateral and two posterior. The lung ultrasound examination is estimated to take around 10 minutes of time.

Sponsors

Mahidol Oxford Tropical Medicine Research Unit
CollaboratorOTHER
University of Kinshasa
CollaboratorOTHER
University of Oxford
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Years to 14 Years
Healthy volunteers
No

Inclusion criteria

* Children aged between 1 and 14 years; * Admitted for confirmed severe malaria (i.e. positive peripheral blood slide for malaria parasite and/or positive rapid diagnostic test for malaria in combination with one or more clinical or laboratory severity criteria detailed below). * Informed consent signed Clinical features of severe malaria * Cerebral malaria; A Glasgow Coma Scale of less than 11 or a Blantyre coma scale less than 3 in preverbal children * Respiratory distress (costal indrawing, use of accessory muscles, nasal flaring, deep breathing or severe tachypnea (respiratory rate \> upper normal limit for age) * Jaundice (visible jaundice) * Circulatory collapse or shock: age \<12 systolic blood pressure \< 70mm Hg; age \> 12 systolic blood pressure \<80mm Hg with cool extremities or capillary refill time \>3 seconds * Spontaneous bleeding * Multiple generalized convulsions: more than two episodes within 24h * Prostration, i.e. generalized weakness so that the patient is unable to sit, stand or walk without assistance Laboratory features and other findings * Metabolic acidosis (venous plasma bicarbonate \< 15mmol/l or base excess \< -2.2mEq/L) * Severe anaemia (age \<12: hematocrit \< 15% or haemoglobin \< 5g/dl; age\>12: hematocrit \< 20% or hemoglobin \< 7 g /dl) * Hypoglycaemia (\< 2.2mmol/l or \< 40mg/dl) * Hyperparasitaemia defined as \> 10% * Hyperlactataemia (venous lactate \< 5 mmol/L) * Kidney dysfunction (blood urea \>20mmol/L)

Exclusion criteria

* Co-morbidity which, in the judgement of the investigator or treating physician, would place the subject at undue risk or interfere with the patient's treatment or results of the study. E.g. immediate transfer needed.

Design outcomes

Primary

MeasureTime frameDescription
Proportion of children diagnosesOn the day of hospital admissionProportion of children diagnosed with (1) respiratory distress with normal lungs (acidosis) in the first 6 hours after hospital admission, (2) concomitant pneumonia, (3) hydrostatic pulmonary oedema, (4) pleural effusion and (5) acute respiratory distress syndrome (ARDS).

Secondary

MeasureTime frameDescription
Proportion of children that fulfill the criteria for a new pulmonary diagnosis >6 hours from admission.From admission to discharge, aproximately 1 weekProportion of children without respiratory symptoms and a normal lung on lung ultrasound on admission that fulfil the criteria for a new pulmonary diagnosis \>6h from admission.
Median lung ultrasound scoreOn the day of hospital admissionMedian lung ultrasound score (range 0 to 36) on the first lung ultrasound performed after admission.
Percentage agreement between a positive lung auscultation (bilateral crepitations) and a lung ultrasound consistent with pulmonary oedema.From hospital admission to discharge, aproximately 1 weekPercentage agreement between a positive lung auscultation (bilateral crepitations) and a lung ultrasound consistent with pulmonary oedema.
Hospital mortality and 30 days mortalityOn hospital discharge, maximum 30 days after admission to hospitalMortality rate in children with severe malaria suffering from a pulmonary complication at admission or during hospitalization and 30 day follow up.

Countries

Democratic Republic of the Congo

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026